Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» liver disease
liver disease
Conatus: Emricasan's 4 Indications Present A Lucrative Opportunity In The Liver Disease Market
Seeking Alpha
Sat, 07/18/15 - 10:48 am
Conatus Pharmaceuticals
emricasan
liver disease
NASH
cirrhosis
New market for liver disease spawns race for better testing
Yahoo/Reuters
Wed, 03/18/15 - 08:20 am
liver disease
NASH
diagnostics
Gilead Sciences to liver disease treatment from Phenex for as much as $470 million
Yahoo/AP
Tue, 01/6/15 - 03:36 pm
Gilead Sciences
Phenex
NASH
liver disease
IPO Stock Watch: FibroGen Up With Liver-Disease Field
Investors.com
Tue, 01/6/15 - 08:41 am
IPOs
FibroGen
liver disease
NASH
Takeda recruits GE to help discover new liver treatments
Fierce Biotech
Tue, 11/11/14 - 01:20 pm
Takeda
GE Healthcare
liver disease
diagnostics
R&D
Biotech stocks to watch ahead of liver disease conference
CNBC
Fri, 11/7/14 - 03:54 pm
liver disease
Gilead Sciences
Intercept Pharma
Genfit
Merck
Achillion
AbbVie
NASH
hepatitis B
hepatitis C
The next hepatitis C? NASH
CNBC
Tue, 07/15/14 - 09:48 am
NASH
hepatitis C
liver disease
nonalcoholic steatohepatitis
Genfit
Gilead Sciences
Intercept Pharma
Intercept Pharma, Government Scientists Spar Over Negative Safety of Liver Drug, Emails Show
TheStreet.com
Tue, 05/20/14 - 09:10 am
Intercept Pharma
liver disease
OCA
obeticholic acid
Shire Acquisition Bolsters Its Rare, And Maybe Not-So-Rare, Disease Portfolio
Seeking Alpha
Mon, 05/19/14 - 09:23 am
Shire
M&A
liver disease
Lumena Pharmaceuticals
LUM001
LUM002
obesity
Lumena swings for a $75M IPO to bear down on liver diseases
Fierce Biotech
Thu, 04/3/14 - 09:30 am
IPOs
Lumena Pharmaceuticals
LUM001
liver disease
Intercept Pharma rises as analyst raises her price and sales estimates for its liver drug OCA
Yahoo/AP
Mon, 02/10/14 - 05:29 pm
OCA
liver disease
Intercept Pharma
Liver Drug Race: Intercept Pharma Vs. Rivals
Seeking Alpha
Mon, 01/27/14 - 08:21 am
Intercept Pharma
liver disease
OCA
Conatus Pharmaceuticals
Gilead Sciences
Galectin
NASH
non-alcoholic fatty liver disease
Intercept CEO says new drug could treat ‘next tsunami’ in liver disease
Marketwatch
Wed, 01/15/14 - 05:21 pm
Intercept Pharma
liver disease
nonalcoholic steatohepatitis
OCA
Intercept stock triples on liver disease study
Yahoo/AP
Fri, 01/10/14 - 08:20 am
Intercept Pharma
liver disease
obeticholic acid
Intercept shares dazzle after early success of PhIIb liver disease drug trial
Fierce Biotech
Thu, 01/9/14 - 09:35 am
Intercept Pharma
liver disease
Does Conatus Pharmaceuticals Have A Winner With Emricasan?
Seeking Alpha
Thu, 09/26/13 - 08:12 am
Conatus Pharmaceuticals
emricasan
Gilead
Merck
Pfizer
liver disease
Sunesis
apoptosis
Data on Cempra's Solithromycin
Yahoo/Zacks
Sat, 09/7/13 - 11:42 am
Cempra
Solithromycin
liver disease
Study of Glaxo platelet drug halted due to clots
Reuters
Thu, 05/13/10 - 09:10 am
GSK
clinical trials
liver disease
Promacta
Raptor's liver disease drug meets mid-stage trial goal
Reuters
Mon, 05/3/10 - 01:09 pm
Raptor Pharmaceuticals
liver disease
Pages
« first
‹ previous
1
2
3